EUVIMEDEUVIMED entdecken
Crossref

Challenges in Launching a Precision Pediatric Oncology Program in Argentina

María Mercedes Paladino iD, Nicolás Pinto, David Verón iD, Fabiana Morosini iD, Hernán García Rivello, Daniela Alves da Quinta, Daiana Ganiewich, Mariana Varela, Blanca Diez, María Teresa de Dávila iD, Milena Villarroel, Karla Emília de Sá Rodrigues iD und 7 weitere

Pediatric Blood & Cancer · 2026-06 · 73 (6)

DOI: 10.1002/1545-5017.70290 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 05.04.2026. Verfasst von María Mercedes Paladino und 18 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigaciones en Medicina Traslacional (IIMT), CONICET, Pilar, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Neoplasms, Medical Oncology, Precision Medicine, Pediatrics. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Bayer, Fondation Nelia et Amadeo Barletta, Fundación Leo Messi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives Advances in pediatric cancer care have underscored the importance of tumor sequencing for diagnosis and treatment selection. However, access to genomic diagnostics in Latin America remains limited. The COPPA Project, an initiative based in Argentina, was conceived to assess the feasibility of delivering clinically useful genomic sequencing for childhood cancers at no cost while maximizing the clinical value of genomic data through multidisciplinary molecular tumor boards (MTBs). Design/Methods Project planning involved securing funding, establishing a sequencing facility, selecting and optimizing an NGS panel, training technical staff in sequencing and interpretation, addressing sample transportation logistics, recruiting oncologists from multiple institutions, and promoting the establishment and participation in a virtual MTB. Tumors underwent sequencing using the Illumina Cancer Childhood Panel. Results were reported and discussed with the treating physicians and during MTB meetings. A survey was administered to MTB participants to assess perceived barriers and facilitators related to the project.

Results

A total of 38 tumors were analyzed, 24 of which were sequenced in‐house. Genomic findings were considered to have clinical utility in 67% of cases. Barriers such as a low demand for studies and oncologists’ lack of time for MTBs were identified. Survey responses highlighted the educational value of the MTBs, with all respondents reporting increased knowledge of precision medicine and greater motivation to adopt genomic testing in clinical practice.

Conclusion

This study identifies key barriers and facilitators encountered in a middle‐income setting. These findings may inform future efforts to implement precision medicine approaches for pediatric cancer in the region.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsMedical OncologyPrecision MedicinePediatricsHumansArgentinaChildFemaleHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

ArgentinaLatin Americaimplementationmolecular tumor boardsprecision oncology

Autor:innen und Institutionen

  • Instituto de Investigaciones en Medicina Traslacional (IIMT), CONICET, Pilar, Buenos Aires, Argentina.
  • Servicio de Oncohematología, Hospital Universitario Austral, Pilar, Buenos Aires, Argentina.
  • Facultad de Ciencias Biomédicas, Universidad Austral, Pilar, Buenos Aires, Argentina.
  • Laboratorio de Terapia Molecular y Celular, Fundación Instituto Leloir-CONICET, Ciudad de Buenos Aires, Argentina.
  • Fundación Pérez Scremini, Montevideo, Uruguay.
  • Departamento de Patología - IMTIB, Hospital Italiano de Buenos Aires, Ciudad de Buenos Aires, Argentina.

ORCID-Profile: María Mercedes Paladino, David Verón, Fabiana Morosini, María Teresa de Dávila, Karla Emília de Sá Rodrigues, Gabriela Villanueva, Alejandra Casanovas, Guillermo L Chantada, Andrea S Llera

Förderung

  • Bayer
  • Fondation Nelia et Amadeo Barletta
  • Fundación Leo Messi
  • Fundación Natalie Dafne Flexer de Ayuda al Niño con Cancer
  • Instituto Nacional del Cáncer
  • Ministry of Science, Technology and Innovative Production, Argentina

Zitieren

APA

Paladino, M. M., Pinto, N., Verón, D., Morosini, F., Rivello, H. G., da Quinta, D. A., Ganiewich, D., Varela, M., Diez, B., de Dávila, M. T., Villarroel, M., Rodrigues, K. E. S., Villanueva, G., Solorzano, D., Casanovas, A., Rotondaro, C., Arrossi, S., Chantada, G. L., & Llera, A. S. (2026). Challenges in Launching a Precision Pediatric Oncology Program in Argentina. Pediatric Blood & Cancer, 73(6). https://doi.org/10.1002/1545-5017.70290

Vancouver

Paladino MM, Pinto N, Verón D, Morosini F, Rivello HG, da Quinta DA, et al. Challenges in Launching a Precision Pediatric Oncology Program in Argentina. Pediatric Blood & Cancer. 2026;73(6). doi:10.1002/1545-5017.70290

BibTeX
@article{Paladino2026,
  author = {Paladino, María Mercedes and Pinto, Nicolás and Verón, David and Morosini, Fabiana and Rivello, Hernán García and da Quinta, Daniela Alves and Ganiewich, Daiana and Varela, Mariana and Diez, Blanca and de Dávila, María Teresa and Villarroel, Milena and Rodrigues, Karla Emília de Sá and Villanueva, Gabriela and Solorzano, Daniel and Casanovas, Alejandra and Rotondaro, Cecilia and Arrossi, Silvina and Chantada, Guillermo L and Llera, Andrea S},
  title = {Challenges in Launching a Precision Pediatric Oncology Program in Argentina},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {6},
  doi = {10.1002/1545-5017.70290}
}
Kostenlos starten →